Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
1
Issued Date
2024-01-01
Resource Type
ISSN
03090167
eISSN
13652559
Scopus ID
2-s2.0-85195451811
Pubmed ID
38845396
Journal Title
Histopathology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Histopathology (2024)
Suggested Citation
Laokulrath N., Gudi M., Salahuddin S.A., Chong A.P.Y., Ding C., Iqbal J., Leow W.Q., Tan B.Y., Tse G., Rakha E., Tan P.H. Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges. Histopathology (2024). doi:10.1111/his.15213 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98806
Title
Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
Corresponding Author(s)
Other Contributor(s)
Abstract
Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody–drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0–1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.